Technical Analysis for OMER - Omeros Corporation

Grade Last Price % Change Price Change
grade F 11.26 1.62% 0.18
OMER closed up 1.62 percent on Tuesday, October 20, 2020, on approximately normal volume. It ran into resistance at its 50 day moving average.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up
Historical OMER trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Stochastic Sell Signal Bearish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Bearish Engulfing Bearish 1.62%
Weak + Overbought Other 1.62%
Weak, Overbought and Reversal Signs Reversal 1.62%
Overbought Stochastic Strength 1.62%
Weak + Overbought Other -2.26%
Older End-of-Day Gignals for OMER ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Support about 9 hours ago
60 Minute Opening Range Breakdown about 14 hours ago
Possible Pocket Pivot about 14 hours ago
1.5x Volume Pace about 15 hours ago
Up 10% about 15 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system. The company derives product candidates from its proprietary PharmacoSurgery platform that is designed to enhance clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological, and other surgical and medical procedures. The company's product candidates include OMS302, which has completed two Phase III clinical trials for use during intraocular lens replacement surgery, including cataract and other lens replacement surgery; OMS103HP that is in Phase III program for use during arthroscopic procedures comprising partial meniscectomy surgery; and OMS201, which has completed Phase I/Phase II studies for use during urological procedures, including ureterscopy for removal of ureteral or renal stones. Its clinical programs also consist of OMS824, which is in Phase I clinical trial for the treatment of cognitive disorders, including schizophrenia; and OMS405 that is in Phase II clinical trial for the treatment and prevention of addiction to substances of abuse. The company's preclinical product development programs comprise OMS721 for hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, wet age-related macular degeneration, ischemia-reperfusion injury, and transplant-related complications; OMS527 for addictions and compulsive disorders, and movement disorders; and OMS616 for surgical and traumatic bleeding. In addition, it is developing G protein-coupled receptors (GPCR) programs for multiple disorders. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.
Medicine Biopharmaceutical Health Surgery Inflammation Clinical Trial Disorders Schizophrenia Ophthalmology Clinical Research Wet Age Related Macular Degeneration Cataract Movement Disorders Cognitive Disorders Surgical Specialties Urology Paroxysmal Nocturnal Hemoglobinuria Arthroscopy Hemolytic Uremic Syndrome

Is OMER a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 25.46
52 Week Low 8.5
Average Volume 1,543,059
200-Day Moving Average 13.52
50-Day Moving Average 11.58
20-Day Moving Average 10.69
10-Day Moving Average 11.17
Average True Range 0.70
ADX 10.26
+DI 24.63
-DI 18.99
Chandelier Exit (Long, 3 ATRs ) 10.16
Chandelier Exit (Short, 3 ATRs ) 11.36
Upper Bollinger Band 11.83
Lower Bollinger Band 9.55
Percent B (%b) 0.75
BandWidth 21.24
MACD Line -0.07
MACD Signal Line -0.20
MACD Histogram 0.1338
Fundamentals Value
Market Cap 691.57 Million
Num Shares 61.4 Million
EPS -2.08
Price-to-Earnings (P/E) Ratio -5.41
Price-to-Sales 5.76
Price-to-Book 0.00
PEG Ratio -0.17
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.99
Resistance 3 (R3) 13.14 12.71 12.70
Resistance 2 (R2) 12.71 12.27 12.63 12.61
Resistance 1 (R1) 11.98 11.99 11.77 11.84 12.51
Pivot Point 11.55 11.55 11.44 11.48 11.55
Support 1 (S1) 10.83 11.11 10.61 10.68 10.01
Support 2 (S2) 10.40 10.84 10.32 9.91
Support 3 (S3) 9.67 10.40 9.82
Support 4 (S4) 9.53